Navigation Links
Jaguar Lumbar I/F Cage System

ProductsJaguar Lumbar I/F Cage System
Company Depuy Spine
Item Jaguar Lumbar I/F Cage System
Features Excellent radiographic visualization of fusion mass. Stiffness matches bone, minimizing stress shielding. Load sharing design to transfer compressive load to bone graft. Open design which Maximizes bone graft-to-endplate surface contact.
Description The Jaguar Lumbar I/F Cage system is a carbon fiber reinforced polymer implant designed to separate the mechanical and biologic functions of posterior lumbar interbody fusion (PLIF). The Jaguar Lumbar I/F Cage provides a device designed to meet the mechanical requirements of PLIF, and uses autologous cancellous bone, the best possible bone for healing. The implant has a modulus of elasticity close to that of human cortical bone, minimizing stress shielding. The cage is radiolucent so that bone healing can be assessed by normal radiographic methods. Indicated for an open posterior approach using autogenous bone graft in patients with Degenerative Disc Disease (DDD) at one or two levels from L2-S1.
Info Depuy Spine
Customer Service: (800) 227-6633

Related medicine products :

1. Jaguar
2. Spine-Tract Anterior Lumbar Retractor System
3. Thompson Surgical Radiotranslucent Anterior Lumbar Retractor System
4. IBS® Allograft Lumbar
5. Horizontal-Vertical (H/V) Lumbar Valve Systems
6. Spine-Tract Posterior Lumbar Retractor System
7. Corlok Lumbar Allograft System
8. Duet Lumbar Allograft System
9. Solo Lumbar Allograft System
10. FastSystem® AF400 Anterior Lumbar Retractor System
11. Karlin Lumbar Microdiscectomy Curette
The proven daily wear spherical soft contact lens.
Surevue brand contact lenses deliver exceptional overall performance in a contact lens since they're easy to use and offer great comfort.
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis.
The Naugle uses reflection mirrors to measure the position of the globe accurately, even after tumor removal or thyroid decompression. It delivers fast, reproducible results. The Naugle is easy to ha
Medicine Products:
(Date:5/16/2008)... HAE: TSX, MONTREAL...ation,(TSX:HAE), a specialty bio-therapeutics comp...rcialization, announced today that its Chairman of...li, will present at the,upcoming Rodman & Renshaw ..., May 20, 2008 in the Zephyr Room at Le Meridien B...
(Date:5/16/2008)... SAO PAULO, Brazil, May 16 /PRNewswire-FirstCall/ ...rs: TEMP3.SA; Bloomberg: TEMP3 BZ), a leading,prov... benefit plans and,specialized assistance services...r of 2008. The operating and financial information...d, is presented in Brazilian Reais and in,accordan...
(Date:5/15/2008)...PHILADELPHIA) Combining natural organic atoms wit...ute have developed a new type of enzyme inhibitor ...ys a key role in cancer development. , Based on...es the way for developing new ways to treat cancer...leads to uncontrolled tumor growth. , Details of...
(Date:5/15/2008)... HARBIN, China, May 15 /Xinhua-PRNewswire-FirstCal...tin Board: CYXI) ("China Yingxia" or "the,Company"...y engaged in the,development, manufacture and dist...plements, and personal care products in the People...inancial results for the first,quarter ended March...
Breaking Medicine News(10 mins):Health News:Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
... - how beneficial traits accumulate in natural pop...he past, two theories have addressed this problem....t confer a cost to their bearer can become common ...y "hitch a ride" with fitter genes that are being ...
...encourage patients with sexually transmitted infec...nd, in some cases, provide home testing kits or dr...dy on bmj.com. Partner notification is an importa...lly transmitted infections, but the stigma attache...
... developed a Vitamin D pill that could give a long...ge of prostrate cancer when given along with chemo...y US drug company Novacea lived for an average of ...ing chemotherapy drug taxotere alone, reported the...
...why we shed tears. But exactly what our tears are ... new study sheds some light on the complex design ...ll tear film, which is made up of three distinct, ... layer – what we normally think of as tears when w...
Other Medicine News:Health News:Study Explains How Costly Traits Evolve 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...
(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...
(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5Phlo Reports Sharp Revenue Increase 3441 1Phlo Reports Sharp Revenue Increase 3441 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4